SLXN
Silexion Therapeutics
$2.53
+$0.26 (+11.45%)Jul 27, 2026
Key metrics
The numbers that frame SLXN today
- Market cap
- $1.06M
- P/E (TTM)
- -0.1
- EV / FCF
- -0.1
- ROIC
- -1,079.3%
- Div yield
- 0%
- Debt / equity
- 6.8
- 52wk Low
- $2.20
- 52wk High
- $223.60
Growth
Revenue and earnings trend for SLXN
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about SLXN
Is Silexion Therapeutics a good buy?
No. Silexion Therapeutics has poor quality and poor momentum. Both signals point to a weaker setup. Growth looks poor. That could put pressure on the long-term business case. We think Silexion Therapeutics is selling at a very high price.
What is the market capitalization of SLXN?
Silexion Therapeutics's market capitalization is $1.06M.
What is the P/E ratio for SLXN stock?
Silexion Therapeutics's current P/E ratio is -0.1.
What is the 52-week high for SLXN stock?
The 52-week high for Silexion Therapeutics is $223.60. The current close of $2.53 is 98.9% below that high.
What is the 52-week low for SLXN stock?
The 52-week low for Silexion Therapeutics is $2.20. The current close of $2.53 is 14.8% above that low.
Does SLXN stock pay dividends?
Silexion Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for SLXN?
Silexion Therapeutics's Debt / Equity ratio is 6.84.